Sudden cardiac death
Introduction
Sudden cardiac death (SCD) is a major contributor to cardiovascular mortality being responsible for approximately 25% of total cardiovascular deaths in the world with a global estimated incidence of 4 million cases per year. 1 {Priori, 2015 #12@@author-year}{Priori, 2015 #12@@hidden}{Priori, 2015 #1}{Priori, 2015 #3}{Priori, 2015 #1}Although ischaemic heart disease accounts for the majority of cases, in patients under 40 years old, inherited structural or purely arrhythmogenic cardiac disorders such as long QT syndrome (LQTS), Brugada syndrome (BS) or Catecholaminergic polymorphic ventricular tachycardia (CPVT) are the main cause of SCD. 2 
Case Report
A 22-year-old man suffered a sudden cardiac arrest without previous symptoms while he was at rest, waiting for a subway train. Cardiopulmonary resuscitation was immediately started using an Automated External Defibrillation that identified the presence of ventricular fibrillation and delivered a shock. Return of spontaneous circulation was achieved after three attempts, being atrial fibrillation (AF) the patient's rhythm at this point ( Figure 1) .
He was admitted to our Cardiovascular Intensive Care Unit and therapeutic hypothermia was performed over a period of 24 h. After completing hypothermia, rewarming, and another 24 h of controlled normothermia the patient awakened with no residual neurologic damage. During hospitalization, structural heart disease was ruled out with a transthoracic echocardiogram, coronary angiography and a cardiac magnetic resonance. Since AF persisted, an elective electrical cardioversion was successfully performed at day four after admission. 12-lead electrocardiogram (ECG) showed a normal QT interval with a corrected QT (QTc) of 423 ms. Continuous ECG monitoring showed no electrical abnormalities after returning to sinus rhythm ( Figure  2 ). An exercise test on treadmill showed no ventricular ectopics or ventricular arrhythmias (VA). QTc interval shortened accordingly and at 4 min of recovery remained <460 ms. Flecainide test was also normal. An implantable cardioverter defibrillator (ICD) was implanted as secondary prevention.
The patient was an exchange student with no previous relevant medical records and all his family lived overseas. The family pedigree was recorded. There was no known history of SCD, unexplained syncope or AF in the family. His mother had died due to a non-cardiac disease and his father and two sisters were alive and apparently healthy. A paternal cousin had also died but the patient was not aware of the details ( Figure 3) .
Next generation sequencing of a set of 76 cardiac disease-related genes identified the heterozygous KCNQ1 missense variant p.Arg231His (R231H) in exon 5. This variant results in the replacement of the normal arginine codon (CGC) with a histidine codon (CAC) at the amino acid position 231 in the S4 domain of the ion channel. It has been previously described in patients with type 1 LQTS (LQT1) and interfamilial early-onset AF. [3] [4] [5] [6] [7] Treatment with beta blockers was started (Nadolol 40 mg twice a day) and genetic counselling given. Unfortunately, we could not study any member of the family so the current status of the relatives is not available. We strongly recommended him to advise all his first-degree relatives for genetic screening and clinical cardiac evaluation with at least a basal ECG, treadmill exercise test and Holter monitoring in order to assess arrhythmic risk in the family and provide preventive care.
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In our case, the patient presented normal ECG intervals and provocative tests were negative for LQTS, BS and CPVT. However, he had lone persistent AF which is a rare finding in a young patient with a structural normal heart. The presence of the KCNQ1 R231H variant was the key point to reach a final diagnosis.
KCNQ1 gene codes for the pore-forming a-subunit Kv7.1 which is a main component of the macromolecular voltagegated potassium channel protein that carries the slowly activated delayed rectifier potassium current (I Ks ). I Ks plays an important role in human cardiac repolarization, particularly at fast rates and when sympathetic tone increases. I Ks has a small amplitude under basal conditions so it is not a major contributing factor to normal repolarization but it is highly recruited when the action potential duration (APD) prolongs and during β-adrenergic stimulation. 8, 9 Therefore, I Ks protects against excessive lengthening of APD and is the main responsible for the adaptation of the APD to heart rate.
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LQT1 is caused by loss-of-function mutations in KCNQ1 gene. The subsequent I Ks current decrease leads to a delayed repolarization, QT interval prolongation and enhanced susceptibility to ventricular arrhythmias, notably torsade de Pointes that occur mainly at exercise and during sympathetic stress. 11 Contrarily, gain of function mutations of the KCNQ1 gene have also been described, resulting in shortening of the APD and the refractory period. Gain of function mutations have been associated with sinus bradycardia, SQTS and familial AF. 7, 12 The KCNQ1 R231H variant is considered a pathogenic mutation. It was first described by Napolitano in a patient with LQTS, though there is no information available regarding the QT interval or the exact phenotype. 3 Posteriorly, other 7 non-related families and 19 carriers have been reported. [4] [5] [6] [7] Interestingly, early-onset AF was the main phenotype in the families whereas most carriers (14) had a normal QT interval. 2 gene carriers presented upper limit QTc: a newborn male with fetal bradycardia 6 and a patient with AF. 7 The 3 remaining patients reviewed are described as having long QT, though in one case long QT was unmasked during infusion of epinephrine 7 and information about the QT interval or the exact phenotype is lacking in the other case. 5 The last patient was a 1 year-old female with LQTS (QTc 479 ms) and AF. 4, 7 Moreover, in a family with early onset AF, a male gene carrier experienced SCD at rest (while sleeping) having normal QT, just as the case of our patient. 7 Even if initially the R231H mutation was associated with LQT1 and it was believed to produce a loss of function of the channel, 6 functional analyses have shown that it indeed accelerates I Ks activation leading to an increased K + efflux (gain-of-function) during the repolarization. At atrial level, the subsequent shortening of the APD and refractoriness may promote reentrant arrhythmias and explain the AF phenotype of the carriers. 7 The question is, however, how a gain of function mutation in KCNQ1 can lead in certain cases to LQTS or may produce a lethal VA even if the QT is not clearly prolonged. Tetrameric phosphorylation of Kv7.1 is required in order to enhance I Ks current in response to β-adrenergic stimulation, a mechanism that is regulated by protein kinase A (PKA). 13 Recent investigations have shown that some LQT1 mutations that are resistant to PKA activation are related to severe phenotypes with high risk of syncope and SCD. 14 Computational modeling suggests that the R231H mutation minimally affect the ventricular APD. Hence, a significant QT prolongation should not be expected in most of the carriers. However, functional analyses show that the mutation impairs the PKA-dependent phosphorylation of the Kv7.1channel. Therefore, in R231H carriers, exercise and sympatheticinduced I Ks increase is prevented at ventricular level. The resistance to PKA phosphorylation might explain how a gain-of-function mutation might also cause abnormal ventricular repolarization under certain circumstances even when it does not produce a lengthening of the ventricular APD. 7 We believe that our case is in accordance to previous literature review. It seems that R231H mutation unique properties lead to a very particular phenotype of early onset AF due to the increase I Ks current at atrial level. Though the QT interval can be upper limit or slightly prolonged, most patients do not present a typical LQTS but they still may have a significant risk of lethal arrhythmias because the ventricular excitability seems to be very abnormal. To the best of our knowledge, this is the second patient reported suffering cardiac arrest and AF who carries the R231H variant. As the case previously reported by Bartos, 7 QT interval was not abnormally prolonged. An interesting observation in our opinion is that in both cases the SCD episode was at rest, a rare finding in KCNQ1 mutations since β-adrenergic stimulation is the main trigger for VA in LQT1 patients. The regulation of the I Ks channel is very complex and other molecules apart from PKA are implicated. Even if a misregulation in the PKA activation has been proposed as an explanation for ventricular abnormal repolarization in KCNQ1 R231H carriers, we think that further investigations are required to fully understand the underlying molecular mechanisms of such particular phenotype.
Clinical and Experimental Cases/Hypothesis
This case illustrates the importance of genetic testing as a tool in the diagnostic approach of unexplained SCD since genetic technologies can diagnose up to 27% of these unexplained cases. 15 The identification of a pathogenic mutation and a deeper study of the effects of its expression besides the genotype itself might provide new insights into the understanding of inherited cardiac disorders.
Conclusions
A significant number of SCD especially in the young remain unexplained after a careful medical investigation. An inherited arrhythmogenic disorder should then be suspected. Genetic testing should be considered in the diagnostic workup in these cases. The identification of a pathogenic mutation and subsequent investigation of the molecular mechanisms underlying the phenotype might provide a personalized diagnosis, care and treatment to patients and their families. 
